US FDA approves Extavia - the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease
Links shared publicly online about this topic.
- 1,809total visits
US FDA approves Extavia - the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease
Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has approved Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.
View full resource at novartis.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Disease and Condition, Drug, FDA, Betaseron, Betaferon, Novartis
Most Recently Shared on August 20, 2009 at 1:30 pm By:
FDA approves Novartis' Extavia® for treatment of MS - http://bit.ly/sM6J3
US FDA Approves Extavia(R) - The First In A New Portfolio Of Planned MS Therapies From Novartis To Help Patients With This Devastating Disease
medicalnewstoday.com — “The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients man” View full resource at medicalnewstoday.com
Most Recently Shared on August 18, 2009 at 12:56 pm By:
MedNewsToday: US FDA Approves Extavia(R) - The First In A New Portfolio Of Planned MS Therapies Fro.. http://bit.ly/MMOBo
Advertisement
